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Abstract
Background: Long-acting muscarinic antagonists (LAMAs) are recommended for the treatment of chronic obstructive
pulmonary disease (COPD). Glycopyrrolate/eFlow® is an investigational drug–device combination of the LAMA
glycopyrrolate administered by an eFlow® Closed System (eFlow® CS) nebulizer. The GOLDEN 2 (NCT01706536)
and GOLDEN 6 (NCT02038829) Phase II, multicenter studies were conducted to inform dose selection for the
GOLDEN Phase III clinical trials. Bronchodilator responses and safety assessments supported dose selection.
Methods: Subjects with moderate-to-severe COPD were randomized into 28-day parallel-group (GOLDEN 2) or
7-day crossover (GOLDEN 6) studies and received placebo, glycopyrrolate (3, 6.25, 12.5, 25, 50 or 100 μg twice
daily [BID]) or aclidinium bromide 400 μg BID. The primary endpoint of both studies was change from baseline in trough
forced expiratory volume in 1 s (FEV1). Safety assessments included the incidence of treatment-emergent adverse events
(TEAEs), treatment-emergent serious adverse events, and discontinuation due to TEAE. Lung function data collected in
both studies were pooled.
Results: The combined GOLDEN 2 (n= 282) and GOLDEN 6 (n = 96) studies included 378 subjects. On Days 7 and 28
there were dose-ordered, statistically significant and clinically important lung function improvements in glycopyrrolate
treatment groups. Specifically, on Day 7, glycopyrrolate produced >0.100 L placebo-adjusted changes from baseline in
trough FEV1 (12.5 μg BID: 0.122 L; 25 μg BID: 0.123 L; 50 μg BID: 0.137 L) and FEV1 AUC0–12 (12.5 μg BID: 0.145 L; 25 μg
BID: 0.178 L; 50 μg BID: 0.180 L). The improvements in lung function for the glycopyrrolate 25 and 50 μg BID doses
were comparable to those with aclidinium bromide 400 μg BID (FEV1: 0.149 L; FEV1 AUC0−12: 0.172 L). Acceptable safety
profiles were observed across all groups in both studies.
Conclusions: The efficacy and safety findings supported selection of glycopyrrolate 25 and 50 μg BID doses for the Phase
III GOLDEN studies and provided preliminary evidence for the use of nebulized glycopyrrolate as a maintenance therapy
for COPD.
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Background
In the United States (US), approximately 12.7 million
adults have a diagnosis of chronic obstructive pulmonary
disease (COPD), with evidence of impaired lung function
in up to 24 million Americans [1]. COPD is the third
leading cause of death and is associated with substantial
medical and economic disease burdens for patients and
healthcare systems [2].
COPD is a heterogeneous disease requiring a spectrum
of treatment options to achieve therapeutic goals [3].
Treatment response may depend on the method of de-
livery, drug preference and tolerability. Use of a metered
dose inhaler (MDI), dry powder inhaler (DPI) or a
nebulizer is appropriate for self-administered COPD
therapy. MDIs and DPIs are widely prescribed, yet up to
70% of COPD patients may not receive an optimal dose
due to an inability to inhale rapidly and forcefully, hold
their breath after dosing, and/or exhale into the device.
Over time, these issues may be associated with subopti-
mal outcomes [4–6].
A survey of 205 US-based pulmonologists indicated
that 63% believed handheld nebulizers may be more
effective than MDIs or DPIs in severe COPD, and 70%
stated that nebulizers are more effective in the manage-
ment of acute exacerbations [7]. Given the prevalence of
COPD, several million US patients may regularly use
nebulizers for COPD; however, treatment compliance
can be affected by the need for frequent dosing with
short-acting bronchodilators, long delivery times
(≥12 min) and limited portability of jet nebulizers. In
addition, standard jet nebulizers have poor delivery
efficiency that may result in suboptimal drug treatment
[8, 9], so there is a need for a new generation of nebu-
lizers that can optimize treatment compliance and de-
liver long-acting bronchodilators into the lung.
Long-acting muscarinic antagonists (LAMAs) play a
central role in the pharmacologic management of COPD
[3]. Currently, there is no nebulized LAMA approved
for use in COPD. Glycopyrrolate/eFlow® is a drug–de-
vice combination of glycopyrrolate administered twice
daily (BID) by an investigational, innovative, vibrating
membrane nebulizer (eFlow® CS; PARI Pharma GmbH,
Starnberg, Germany). The eFlow® CS device delivers an
acceptable respirable fraction (72% fine particle fraction)
of glycopyrrolate aerosol droplets (3.7 μm mass median
aerodynamic diameter, 1.7 geometric standard deviation)
into the lung within 3 min with tidal breathing [10], is
silent, portable, does not require patient preparation of
the drug product, and is amenable to caregiver assist-
ance. The shorter delivery time and portability may ad-
dress the treatment compliance issues that have been
reported with non-portable nebulizers. Nebulized glyco-
pyrrolate delivery occurs over multiple tidal breaths,
rather than during a single breath attempt, and may
provide a therapeutic alternative for patients who experi-
ence difficulty operating handheld devices, exacerbate,
and/or are physiologically unable to generate sufficient
inspiratory pressure for inhaler use [11–14].
The Glycopyrrolate for Obstructive Lung Disease via
Electronic Nebulizer (GOLDEN) 2 and GOLDEN 6
studies were conducted to inform dose selection for the
GOLDEN Phase III clinical trials by characterizing the
bronchodilator dose–response relationship and safety
profiles of nebulized glycopyrrolate doses administered
BID in subjects with moderate-to-severe COPD. Lung
function data are presented pooled across both studies
and individually.
Methods
Study design and treatment
The GOLDEN 2 study was initiated in October 2012
and completed in April 2013. GOLDEN 6 was initiated
in January 2014 and completed in May 2014. The study
protocols were approved by an Institutional Review
Board and were conducted in accordance with the
approved protocols, the International Council for
Harmonization Good Clinical Practice guidelines, and
the Declaration of Helsinki. All subjects provided written
informed consent prior to undergoing any study
procedures.
In the GOLDEN 2 study, subjects were randomized to
one of five treatment groups following a 1-week placebo
run-in period, and stratified by inhaled corticosteroid
use and participation (yes/no) in serial spirometry as-
sessments. The subjects received placebo, glycopyrrolate
12.5, 25, 50, or 100 μg BID for 28 days in a double-blind
manner (Fig. 1).
GOLDEN 6 used a complete crossover study design,
with subjects randomized to a treatment sequence con-
sisting of six 7-day treatment periods followed by a 5- to
7-day washout (Fig. 2). During each treatment period,
subjects received placebo, glycopyrrolate 3, 6.25, 12.5, or
50 μg BID, or aclidinium bromide (Tudorza® Pressair®,
AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA)
400 μg BID in the morning and evening. All glycopyrro-
late and placebo treatments were administered double-
blinded by the investigational eFlow® CS nebulizer;
dosing of aclidinium bromide was open label.
Patients
Eligible male and female subjects were 35 to 75
(GOLDEN 2) and 40 to 65 (GOLDEN 6) years old with
a minimum 10 pack-year smoking history and a clinical
diagnosis of moderate-to-severe COPD (GOLD 2011)
[15]. Additional inclusion criteria were a forced expira-
tory volume in 1 s (FEV1) between 30% and 70%
(GOLDEN 2) and 40% and 70% (GOLDEN 6) of the pre-
dicted normal, an FEV1/forced vital capacity ratio <0.70
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and demonstrated reversibility (FEV1 ≥12% and 0.100 L)
following post-bronchodilator (inhalation of ipratropium
bromide) spirometry at screening. Subjects with current
or history of unstable cardiac and/or respiratory disease
(including asthma) or unstable comorbidities were ex-
cluded. Other exclusion criteria included systemic
steroid therapy, respiratory infection, and a COPD
exacerbation requiring hospitalization or need for in-
creased treatments for COPD within 1.5 to 3 months of
screening. Subjects using oxygen therapy for >10 h daily
were also excluded.
Study objectives and endpoints
The primary objective of both studies was to confirm
the efficacy and dose–response relationship of glycopyr-
rolate BID in subjects with moderate-to-severe COPD,
and identify doses for the GOLDEN Phase III clinical tri-
als. Safety and tolerability of glycopyrrolate/eFlow® were
secondary objectives.
The GOLDEN 2 primary efficacy endpoint was change
from baseline in morning trough FEV1 on Day 28. Sec-
ondary endpoints included standardized change from
baseline in both FEV1 area under the curve from 0 to
12 h (AUC0–12) and peak FEV1 on Day 28. Other end-
points included change from baseline in FEV1 AUC0–12
and trough FEV1 on Day 7.
The primary and secondary efficacy endpoints for
GOLDEN 6 were placebo-adjusted change from base-
line in morning trough FEV1 and standardized change
from baseline in FEV1 AUC0−12, both on Day 7.
Safety assessments included the incidence of treatment-
emergent adverse events (TEAEs), serious TEAEs, discon-
tinuations due to TEAEs, changes in clinical laboratory
assessments, vital signs and electrocardiograms (ECG, in-
cluding QT interval), and physical examination findings.
Vital signs, clinical laboratory assessments, and ECG were
collected at Days 1, 7 and 28 for GOLDEN 2, and at Days
1 and 7 for GOLDEN 6.
Fig. 1 GOLDEN 2 study design. BID, twice daily
Fig. 2 GOLDEN 6 study design. aSafety follow-up was conducted 5–7 days after the Early Termination visit for subjects who discontinued the
study prior to completing all scheduled treatment periods. BID, twice daily
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Statistical analyses
For GOLDEN 2, 45 subjects per treatment arm were re-
quired to provide approximately 80% power to detect a
treatment difference of 0.12 L in the primary efficacy
endpoint (mean change in trough FEV1) between each
glycopyrrolate dose group and placebo (at a significance
level of 0.05, assuming a standard deviation [SD] of
0.200 L and using a two-sided test). For GOLDEN 6, 66
subjects were required to provide approximately 90%
power to detect a treatment difference of 0.10 L in
the primary efficacy endpoint (mean change in
trough FEV1) between each glycopyrrolate dose
group and placebo (at a significance level of 0.0125,
assuming an SD of 0.176 L and using a two-sided
test). Additional subjects (total n = 78) were required
in GOLDEN 6 for the trial to have sufficient power
for the key secondary endpoint, FEV1 AUC0–12.
Accounting for potential dropouts, the planned en-
rollment for GOLDEN 2 was 275 subjects and 96
subjects for GOLDEN 6.
All subjects who were randomized and received at
least one dose of study drug were included in the statis-
tical analyses of baseline characteristics, efficacy, and
safety. Missing data were treated as missing at random.
Sensitivity analyses were performed to assess the impact
of missing data.
Each study was analyzed separately. Subsequently,
the data were pooled to increase the sample size in
the overlapping glycopyrrolate dose groups (12.5 and
50 μg BID) and fully characterize the dose–response
profile. Pooling of these Phase II data was justified
based on the overlap of doses, BID dose regimen,
blinding of doses, nebulizer device, time points, simi-
larity of study populations, and primary endpoint
(trough FEV1).
Trough FEV1 was calculated as the mean of two FEV1
values obtained between 23 and 24 h after the morning
dose of study drug on Day 7 (GOLDEN 6) or Day 28
(GOLDEN 2). Change in trough FEV1 was calculated as
trough FEV1 minus baseline FEV1 (the mean of two
FEV1 values obtained at 45 and 15 min prior to the
morning dose on Day 1).
Least squares (LS) means and 95% confidence intervals
(CIs) for the pooled study data were derived from an
analysis of covariance (ANCOVA) model with change
from baseline in trough FEV1 or FEV1 AUC0–12 as the
response variable, a factor for treatment group, and with
baseline FEV1 as a covariate.
Safety parameters were analyzed descriptively for
the safety population. All adverse events (AEs) were
classified using the Medical Dictionary for Regulatory
Activities Version 15.1.
All statistical procedures were performed using SAS®
Version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Patient demographics and baseline characteristics
A total of 282 subjects were randomized in GOLDEN 2,
and 96 were randomized in GOLDEN 6. In the pooled
population of 378 subjects, 27 (7%) discontinued; the
most frequent reason was AEs (14 [5%] in GOLDEN 2
and 5 [5.2%] in GOLDEN 6).
Pooled patient demographics and baseline characteris-
tics are presented in Table 1 (data for the individual
studies are available in Additional file 1: Tables S1 and
S2). Mean age was 59 years (range: 40–75 years). Most
subjects were white (90%) and 52% were female. The
proportion of subjects with severe COPD ranged from
37.2% to 51.9%. The majority of subjects (60.3%) were
current smokers and the mean duration of smoking his-
tory ranged from 50.1 to 54.0 pack-years.
Treatment compliance during the double-blind treat-
ment period was 95.8–97.2% across treatment groups in
GOLDEN 2, and 98.9–99.3% in GOLDEN 6.
Efficacy
In the pooled data, nebulized glycopyrrolate showed sig-
nificant improvements in change from baseline in trough
FEV1 and FEV1 AUC0−12 on Day 7 (Tables 2 and 3).
Individual study data for the glycopyrrolate doses of 12.5
and 50 μg BID are reported below and for the remaining
treatment groups in Additional file 1: Tables S3–S7.
Change from baseline in trough FEV1
Glycopyrrolate 12.5 and 50 μg BID showed significant
improvement in LS mean placebo-adjusted change from
baseline in trough FEV1 on Day 7 and Day 28 in
GOLDEN 2, and on Day 7 in GOLDEN 6 (GOLDEN 2,
Day 7: 0.118 and 0.149 L; GOLDEN 2, Day 28: 0.117
and 0.146 L; GOLDEN 6, Day 7: 0.109 and 0.138 L, re-
spectively) (Additional file 1: Tables S3 and S4). Change
from baseline in FEV1 over 24 h on Day 28 (GOLDEN
2) and Day 7 (GOLDEN 6), for all doses, is presented in
Additional file 1: Figs. S1 and S2.
For the pooled data, the change from baseline in
trough FEV1 on Day 7 was significantly greater for all
doses of nebulized glycopyrrolate (except the glyco-
pyrrolate 3 μg BID) than for placebo (Table 2, Fig. 3).
The placebo-adjusted LS mean change from baseline
on Day 7 showed dose-related increases in trough
FEV1 of 0.122, 0.123, 0.137, and 0.169 L for the gly-
copyrrolate 12.5, 25, 50, and 100 μg BID doses
respectively. Placebo-adjusted changes from baseline
in trough FEV1 of subjects who received glycopyrro-
late 50 μg BID showed similar increases to those of
subjects who received aclidinium bromide (0.137 and
0.149 L, respectively).
Donohue et al. Respiratory Research  (2017) 18:202 Page 4 of 9
Change from baseline in FEV1 AUC0–12
In GOLDEN 2, on Day 7 (Fig. 4a) and Day 28, both
glycopyrrolate 12.5 and 50 μg BID doses produced
significant increases in LS mean placebo-adjusted
change from baseline in FEV1 AUC0–12 (Day 7: 0.143
and 0.153 L; Day 28: 0.136 and 0.105 L, respectively;
Additional file 1: Table S5).
Increases in LS mean placebo-adjusted change from
baseline in FEV1 AUC0–12 on Day 7 (Fig. 4b) in
GOLDEN 6 were observed for both glycopyrrolate
12.5 μg BID (0.126 L) and 50 μg BID (0.196 L), with the
improvement for glycopyrrolate 50 μg BID being
comparable to that with aclidinium 400 μg BID (0.190 L)
(Additional file 1: Table S6).
In the pooled data, on Day 7, a dose-related improve-
ment was apparent for glycopyrrolate, in terms of the
placebo-adjusted standardized change from baseline in
FEV1 AUC0–12 (Table 3; Fig. 4c). Compared with the pla-
cebo-adjusted change in FEV1 AUC0–12 versus base-
line with aclidinium 400 μg BID (0.172 L), there was
less improvement with glycopyrrolate 12.5 μg BID
(0.145 L), and more improvement with glycopyrrolate
25 μg BID (0.178 L) and glycopyrrolate 50 μg BID
(0.180 L).
Table 1 Patient demographics and baseline characteristics (pooled population)
Parameter Placebo Glycopyrrolate Aclidinium Total
(n = 149) 3 μg BID
(n = 91)
6.25 μg BID
(n = 92)
12.5 μg BID
(n = 145)
25 μg BID
(n = 54)
50 μg BID
(n = 149)
100 μg BID
(n = 59)
400 μg BID
(n = 94)
(N = 378)
Mean (SD) age, years 57.7 (7.65) 54.5 (5.90) 54.4 (5.90) 56.9 (7.37) 59.6 (8.98) 56.4 (7.49) 59.4 (7.65) 54.6 (5.92) 59.0 (8.05)
Age <65 years, n (%) 120 (80.5) 89 (97.8) 90 (97.8) 124 (85.5) 40 (74.1) 126 (84.6) 42 (71.2) 92 (97.9) 278 (73.5)
Gender, n (%)
Female 80 (53.7) 49 (53.8) 49 (53.3) 76 (52.4) 30 (55.6) 73 (49.0) 34 (57.6) 50 (53.2) 197 (52.1)
Male 69 (46.3) 42 (46.2) 43 (46.7) 69 (47.6) 24 (44.4) 76 (51.0) 25 (42.4) 44 (46.8) 181 (47.9)
Race, n (%)
White 131 (87.9) 81 (89.0) 83 (90.2) 132 (91.0) 51 (94.4) 135 (90.6) 49 (83.1) 84 (89.4) 339 (89.7)
Black/African American 17 (11.4) 10 (11.0) 9 (9.8) 13 (9.0) 3 (5.6) 13 (8.7) 10 (16.9) 10 (10.6) 37 (9.8)
American Indian/Alaskan Native 1 (0.7) 0 0 0 0 1 (0.7) 0 0 2 (0.5)
Post-bronchodilator FEV1, n (%)
<50% predicted 60 (40.3) 34 (37.4) 34 (37.0) 59 (40.7) 28 (51.9) 62 (41.6) 25 (42.4) 35 (37.2) NA
≥50% predicted 89 (59.7) 57 (62.6) 58 (63.0) 86 (59.3) 26 (48.1) 87 (58.4) 34 (57.6) 59 (62.8) NA
BID twice daily, FEV1 forced expiratory volume in 1 s, NA not available, SD standard deviation
Table 2 Change from baseline in trough FEV1 on Day 7 (pooled population)
Parameter Placebo Glycopyrrolate Aclidinium
(n = 149) 3 μg BID
(n = 91)
6.25 μg BID
(n = 92)
12.5 μg BID
(n = 145)
25 μg BID
(n = 54)
50 μg BID
(n = 149)
100 μg BID
(n = 59)
400 μg BID
(n = 94)
Baseline FEV1
n 149 91 92 144 54 149 59 94
Mean (SD), L 1.296 (0.429) 1.363 (0.429) 1.380 (0.440) 1.302 (0.421) 1.205 (0.425) 1.321 (0.433) 1.202 (0.463) 1.395 (0.464)
FEV1 on Day 7
n 139 86 88 137 51 139 57 86
Mean (SD), L 1.304 (0.419) 1.375 (0.422) 1.454 (0.482) 1.396 (0.435) 1.313 (0.434) 1.436 (0.440) 1.359 (0.491) 1.508 (0.434)
Change from baseline in FEV1 on Day 7
Mean (SD), L −0.024 (0.214) −0.012 (0.186) 0.063 (0.200) 0.100 (0.193) 0.108 (0.202) 0.113 (0.214) 0.154 (0.170) 0.120 (0.187)
LS mean (SE), L −0.024 (0.017) −0.007 (0.021) 0.068 (0.021) 0.097 (0.017) 0.099 (0.028) 0.113 (0.017) 0.145 (0.026) 0.125 (0.021)
95% CI −0.057, 0.009 −0.049, 0.034 0.026, 0.109 0.064, 0.131 0.045, 0.153 0.081, 0.146 0.094, 0.196 0.083, 0.167
Placebo-adjusted change from baseline in FEV1 on Day 7
LS mean (SE), L – 0.017 (0.027) 0.092 (0.027) 0.122 (0.024) 0.123 (0.032) 0.137 (0.024) 0.169 (0.031) 0.149 (0.027)
95% CI – −0.036, 0.070 0.039, 0.144 0.075, 0.168 0.060, 0.186 0.091, 0.184 0.108, 0.230 0.096, 0.202
BID twice daily, CI confidence interval, FEV1 forced expiratory volume in 1 s, LS least squares, SD standard deviation, SE standard error
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Change from baseline in peak FEV1 (GOLDEN 2 only)
At Day 28, in GOLDEN 2, improvements were seen in
placebo-adjusted change from baseline in peak FEV1 for all
glycopyrrolate doses including 12.5 and 50 μg BID (0.168
and 0.165 L, respectively) (Additional file 1: Table S7).
Characterization of the dose–response relationship for
glycopyrrolate/eFlow®
Improvements in placebo-adjusted trough FEV1 with neb-
ulized glycopyrrolate were clinically meaningful within the
dose range of 12.5 to 100 μg BID. Although the group
mean changes with glycopyrrolate 12.5 μg BID were
>0.100 L, the lower bound of the 90% CI was <0.100 L. In
addition, a statistical comparison between the 12.5 μg and
50 μg groups in GOLDEN 6 showed that the 50 μg BID
dose was statistically superior, as measured by change
from baseline in FEV1 AUC0–12. Exploratory model-fitting
indicated that a sigmoidal model was the best fit to the
trough FEV1 data, and showed that glycopyrrolate doses
of 3 to 50 μg were situated on the monotonically increas-
ing dose–response curve.
Safety
Treatment-emergent adverse events
Overall, TEAEs were reported for 87 subjects in
GOLDEN 2, and for 62 subjects in GOLDEN 6. In
GOLDEN 2, the total incidence of TEAEs was com-
parable between the placebo group (26%) and the gly-
copyrrolate groups (12.5 μg BID, 35%; 25 μg BID,
33%; 50 μg BID, 32%; 100 μg BID, 29%; Table 4).
Similar TEAE incidences were observed in the treat-
ment groups in GOLDEN 6 (glycopyrrolate 3 μg BID,
24%; 6.25 μg BID, 25%; 12.5 μg BID, 27%; 50 μg BID,
15%; aclidinium 400 μg BID, 26%), with an incidence
of 12% in the placebo group. The most frequent
TEAEs seen with glycopyrrolate were COPD exacer-
bation (1.7–7.4%; placebo 1.8%) and headache (0–
5.1%; placebo 1.8%) in GOLDEN 2, and hypertension
Table 3 Standardized change from baseline in FEV1 AUC0–12 on Day 7 (pooled population)
Parameter Placebo Glycopyrrolate Aclidinium
(n = 149) 3 μg BID
(n = 91)
6.25 μg BID
(n = 92)
12.5 μg BID
(n = 145)
25 μg BID
(n = 54)
50 μg BID
(n = 149)
100 μg BID
(n = 59)
400 μg BID
(n = 94)
Baseline FEV1
n 149 91 92 144 54 149 59 94
Mean (SD), L 1.296 (0.429) 1.363 (0.429) 1.380 (0.440) 1.302 (0.421) 1.205 (0.425) 1.321 (0.433) 1.202 (0.463) 1.395 (0.464)
Standardized change from baseline in FEV1 AUC0–12 on Day 7
n 146 91 92 143 53 146 59 90
Mean (SD), L −0.016 (0.187) 0.034 (0.178) 0.068 (0.181) 0.130 (0.174) 0.167 (0.200) 0.163 (0.201) 0.210 (0.143) 0.153 (0.224)
LS mean (SE), L −0.016 (0.016) 0.036 (0.020) 0.071 (0.020) 0.129 (0.016) 0.162 (0.026) 0.163 (0.016) 0.205 (0.025) 0.156 (0.020)
95% CI −0.047, 0.014 −0.003, 0.074 0.032, 0.109 0.098, 0.160 0.112, 0.213 0.133, 0.194 0.157, 0.253 0.117, 0.195
Placebo-adjusted change from baseline in FEV1 AUC0–12 on Day 7
LS mean (SE), L – 0.052 (0.025) 0.087 (0.025) 0.145 (0.022) 0.178 (0.030) 0.180 (0.022) 0.221 (0.029) 0.172 (0.025)
95% CI – 0.003, 0.101 0.038, 0.136 0.102, 0.188 0.120, 0.237 0.137, 0.223 0.164, 0.278 0.123, 0.221
AUC area under the curve, BID twice daily, CI confidence interval, FEV1 forced expiratory volume in 1 s, LS least squares, SD standard deviation, SE standard error
Fig. 3 Mean change from baseline in FEV1 over time on Day 7 (pooled population). BID, twice daily. FEV1, forced expiratory volume in 1 second
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(1.1–4.4%; placebo 0%) and cough (3.3–6.7%; placebo
2.2%) in GOLDEN 6.
Neither study showed evidence of a dose-related rela-
tionship in terms of the incidence of any specific TEAE.
In subjects treated with aclidinium 400 μg BID, the most
common TEAEs were dysgeusia (8.5%), and bronchitis,
cough, and nausea (all 2.1%).
Discontinuations due to TEAEs are presented in Table 4.
Serious treatment-emergent adverse events and deaths
The overall incidence of serious TEAEs reported for
glycopyrrolate/eFlow® was comparable to that for
placebo and aclidinium (GOLDEN 2: placebo, 3.5%; gly-
copyrrolate 12.5 μg BID, 3.6%; 25 μg BID, 3.7%; 50 μg
BID, 1.8%; 100 μg BID, 5.1%. GOLDEN 6: placebo,
1.1%; glycopyrrolate 3 μg BID, 0%; 6.25 μg BID, 2.2%;
12.5 μg BID, 1.1%; 50 μg BID, 0%; aclidinium 400 μg
BID, 3.2%; Table 4). The only serious TEAE to occur in
more than one subject receiving glycopyrrolate was
COPD exacerbation, which occurred in two subjects in
GOLDEN 2 (one in the 25 μg BID and one in the
100 μg BID dose groups) and two subjects in GOLDEN
6 (one in the 6.25 μg BID and one in the 12.5 μg BID
dose groups).
a
b
c
Fig. 4 Placebo-adjusted change from baseline in FEV1 AUC0-12 on Day 7 (a: GOLDEN 2; b: GOLDEN 6; c: pooled population). AUC, area under the
curve. BID, twice daily. CI, confidence interval. FEV1, forced expiratory volume in 1 second. LS, least squares
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Two subjects died, one in GOLDEN 2 (a female sub-
ject who had severe cardiac arrest prior to receiving
double-blind medication) and one in GOLDEN 6 (a
male with presumed poly-drug [i.e. opiate] toxicity 2 days
after the last dose of glycopyrrolate 6.25 μg BID, which
was not considered to be treatment related).
Vital signs, clinical laboratory, and electrocardiogram
parameters
In both studies, no clinically meaningful findings or
trends were noted in vital signs, clinical laboratory as-
sessments, or ECG (including QTc-F) parameters be-
tween treatment groups (data not shown).
Discussion
This analysis of pooled data from two Phase II random-
ized, placebo- and/or active-controlled studies was con-
ducted to characterize the dose–response relationship for
nebulized glycopyrrolate, and inform dose selection for
the Phase III studies. In subjects with moderate-to-severe
COPD, treatment with glycopyrrolate/eFlow® was associ-
ated with significant improvements in pulmonary function
versus placebo, and was generally well tolerated.
Analysis of the pooled population suggests a sigmoidal
dose–response relationship. Glycopyrrolate 3 μg BID
was deemed the ‘no effect’ dose, with doses up to 50 μg
BID situated on the monotonically increasing curve,
indicating increased response with increasing dose. The
glycopyrrolate 6.25 μg BID and 12.5 μg BID doses had
statistically significant but clinically suboptimal effects.
At doses of 25 and 50 μg BID, clinically meaningful im-
provements in the change from baseline in trough FEV1
and change from baseline in FEV1 AUC0–12 were ob-
served, compared with placebo, with greater improve-
ments seen with 50 μg BID than with 25 μg BID. These
improvements with glycopyrrolate/eFlow® were either
comparable or superior to those observed with aclidi-
nium 400 μg BID. Based on these data, glycopyrrolate
doses of 25 μg BID and 50 μg BID were selected for
further evaluation. Pooled and individual study data sup-
ported the dose selection.
Although previous studies with glycopyrrolate/eFlow®
administered once daily (QD) showed statistically signifi-
cant increases in trough FEV1 [16, 17], a substantial
incremental improvement was seen with BID dosing.
Glycopyrrolate 50 μg QD administered for 7 days im-
proved the trough FEV1 by 0.068 L, while the pooled
improvement in trough FEV1 with glycopyrrolate 50 μg
BID for 7 days was 0.137 L in these studies.
Conclusion
In the Phase II GOLDEN 2 and 6 studies, the statistical
and clinical improvements in lung function, relative to
placebo on Days 7 and 28, and acceptable safety profile
support the selection of the glycopyrrolate 25 and
50 μg BID doses for the GOLDEN Phase III program.
The combined study results provide preliminary evi-
dence for the use of nebulized glycopyrrolate BID as a
maintenance therapy for the treatment of COPD. Neb-
ulized glycopyrrolate may provide patients and physi-
cians with an additional treatment option for
moderate-to-severe COPD, and provide a therapeutic
alternative for patients who experience physical and/or
physiological difficulty using handheld inhalers.
Additional file
Additional file 1 Online Supplementary Data. Table S1. Patient demographics
and baseline characteristics, GOLDEN 2 (ITT population). Table S2. Patient
demographics and baseline characteristics, GOLDEN 6 (safety population).
Table S3. Change from baseline in trough FEV1 on Day 7 and Day 28,
GOLDEN 2 (ITT population). Table S4. Change from baseline in trough FEV1
on Day 7, GOLDEN 6 (efficacy population). Table S5. Standardized change
from baseline in FEV1AUC0–12 on Day 7 and Day 28, GOLDEN 2 (ITT
population). Table S6. Standardized change from baseline in FEV1
AUC0–12 on Day 7, GOLDEN 6 (efficacy population). Table S7. Change
from baseline in peak FEV1 on Day 28, GOLDEN 2 (ITT population). Figure
S1. Least squares mean change from baseline in FEV1 over time on Day 28
(GOLDEN 2 Substudya ITT population). Figure S2. Mean change from
baseline in FEV1 over time on Day 7 (GOLDEN 6 efficacy population). (DOCX
269 kb)
Table 4 Summary of treatment-emergent adverse events
GOLDEN 2 GOLDEN 6
Placebo Glycopyrrolate Placebo Glycopyrrolate Aclidinium
(n = 57) 12.5 μg
BID
(n = 55)
25 μg
BID
(n = 54)
50 μg
BID
(n = 57)
100 μg
BID
(n = 59)
(n = 92) 3 μg
BID
(n = 91)
6.25 μg
BID
(n = 92)
12.5 μg
BID
(n = 90)
50 μg
BID
(n = 92)
400 μg
BID
(n = 94)
Any TEAE, n (%) 15 (26.3) 19 (34.5) 18 (33.3) 18 (31.6) 17 (28.8) 11 (12.0) 22 (24.2) 23 (25.0) 24 (26.7) 14 (15.2) 24 (25.5)
Potentially related
TEAEa, n (%)
0 5 (9.1) 2 (3.7) 2 (3.5) 4 (6.8) 4 (4.3) 5 (5.5) 5 (5.4) 9 (10.0) 7 (7.6) 11 (11.7)
Serious TEAE, n (%) 2 (3.5) 2 (3.6) 2 (3.7) 1 (1.8) 3 (5.1) 1 (1.1) 0 2 (2.2) 1 (1.1) 0 3 (3.2)
Discontinuations
due to TEAE, n (%)
2 (3.5) 3 (5.5) 4 (7.4) 3 (5.3) 1 (1.7) 1 (1.1) 0 0 1 (1.1) 0 2 (2.1)
BID twice daily, TEAE treatment-emergent adverse event
aConsidered by the Investigator to have a definite, probable, or possible relationship to study drug
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